NASDAQ:OPTR - Optimer Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive OPTR News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:OPTR
CUSIP68401H10
Phone+1-201-3338819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions

What is Optimer Pharmaceuticals' stock symbol?

Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."

Has Optimer Pharmaceuticals been receiving favorable news coverage?

Media coverage about OPTR stock has trended positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Optimer Pharmaceuticals earned a news impact score of 2.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near term.

What other stocks do shareholders of Optimer Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Optimer Pharmaceuticals investors own include Sirius XM (SIRI), ShoreTel (SHOR), PennantPark Investment (PNNT), Hansen Medical (HNSN), Geron (GERN), Glacier Bancorp (GBCI), 8X8 (EGHT), Polarityte (COOL), Abraxas Petroleum (AXAS) and Ares Capital (ARCC).

How do I buy shares of Optimer Pharmaceuticals?

Shares of OPTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Optimer Pharmaceuticals' official website?

The official website for Optimer Pharmaceuticals is http://www.optimerpharma.com.

How can I contact Optimer Pharmaceuticals?

Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.


MarketBeat Community Rating for Optimer Pharmaceuticals (NASDAQ OPTR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel